公开(公告)号：US20190021831A1

公开(公告)日：2019-01-24

申请号：US15895876

申请日：2018-02-13

Applicant: MERIAL INC.

Inventor： Aurelie de Malibran-Santibanez ,  Alonso Prado-Masias ,  Frederic David

IPC: A61D1/02 ,  A61K39/02 ,  A61J1/20 ,  A61M3/00

Abstract: The invention relates to a liquid applicator, for administering liquids, including vaccines, to animals. In particular, the applicator is useful for delivering liquids to mouths of animals.

公开(公告)号：US20170137843A1

公开(公告)日：2017-05-18

申请号：US15410588

申请日：2017-01-19

Applicant: MERIAL, INC.

Inventor： Teshome Mebatsion ,  Jules Maarten Minke ,  Frederic David

IPC: C12N15/86 ,  A61K39/205

CPC classification number: C12N15/86 ,  A61K39/008 ,  A61K39/12 ,  A61K39/205 ,  A61K39/39 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/55516 ,  C12N15/8633 ,  C12N2710/24043 ,  C12N2760/20134

Abstract: The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus

公开(公告)号：US20190000965A1

公开(公告)日：2019-01-03

申请号：US16109570

申请日：2018-08-22

Applicant: MERIAL, INC.

Inventor： Frederic David ,  Zahia Hannas-Djebbara ,  Herve Poulet ,  Jules Maarten Minke

IPC: A61K39/23

Abstract: The present disclosure encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs are formed by the CPV VP2 protein. Further, the disclosure broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.

公开(公告)号：US20170087244A1

公开(公告)日：2017-03-30

申请号：US15265545

申请日：2016-09-14

Applicant: MERIAL, INC.

Inventor： Frederic David ,  Zahia Hannas-Djebbara ,  Herve Poulet ,  Jules Maarten Minke

IPC: A61K39/23 ,  C07K14/005 ,  C12N7/00 ,  A61K39/135

CPC classification number: A61K39/23 ,  A61K39/12 ,  A61K39/135 ,  A61K2039/5258 ,  A61K2039/545 ,  A61K2039/552 ,  A61K2039/575 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2750/14323 ,  C12N2750/14334 ,  C12N2750/14371 ,  C12N2770/32123 ,  C12N2770/32134

Abstract: The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs provided by the invention are formed by the CPV VP2 protein. Further, the invention broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.

公开(公告)号：US10006050B2

公开(公告)日：2018-06-26

申请号：US15410588

申请日：2017-01-19

Applicant: MERIAL, INC.

Inventor： Teshome Mebatsion ,  Jules Maarten Minke ,  Frederic David

IPC: C12N15/63 ,  C12N15/86 ,  C12N15/863 ,  A61K39/008 ,  A61K39/12 ,  A61K39/39 ,  A61K39/205 ,  A61K39/00

CPC classification number: C12N15/86 ,  A61K39/008 ,  A61K39/12 ,  A61K39/205 ,  A61K39/39 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/55516 ,  C12N15/8633 ,  C12N2710/24043 ,  C12N2760/20134

Abstract: The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus.

公开(公告)号：US10080798B2

公开(公告)日：2018-09-25

申请号：US15265545

申请日：2016-09-14

Applicant: MERIAL, INC.

Inventor： Frederic David ,  Zahia Hannas-Djebbara ,  Herve Poulet ,  Jules Maarten Minke

IPC: A61K39/23 ,  C07K14/005 ,  C12N7/00 ,  A61K39/135 ,  A61K39/12 ,  A61K39/00

CPC classification number: A61K39/23 ,  A61K39/12 ,  A61K39/135 ,  A61K2039/525 ,  A61K2039/5258 ,  A61K2039/545 ,  A61K2039/552 ,  A61K2039/575 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2750/14323 ,  C12N2750/14334 ,  C12N2750/14371 ,  C12N2770/32123 ,  C12N2770/32134

Abstract: The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs provided by the invention are formed by the CPV VP2 protein. Further, the invention broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.